Dirucotide misses Phase III endpoint

BioMS Medical Corp. (TSX:MS) and Eli Lilly and Co. (NYSE:LLY) said dirucotide missed the primary endpoint of a delay in disease progression versus placebo in the Phase III MAESTRO-01 trial in 612 patients with secondary progressive multiple sclerosis (SPMS). The companies said they would halt MAESTRO-02, an open-label extension of MASETRO-01, and the Phase III MAESTRO-03 of dirucotide to treat SPMS and review available data. ...